Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential COVID-19 Therapeutics

SARS-CoV-2 has an exonuclease-based proofreader, which removes nucleotide inhibitors such as Remdesivir that are incorporated into the viral RNA during replication, reducing the efficacy of these drugs for treating COVID-19. Combinations of inhibitors of both the viral RNA-dependent RNA polymerase a...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:bioRxiv
Autori principali: Wang, Xuanting, Sacramento, Carolina Q., Jockusch, Steffen, Chaves, Otávio Augusto, Tao, Chuanjuan, Fintelman-Rodrigues, Natalia, Chien, Minchen, Temerozo, Jairo R., Li, Xiaoxu, Kumar, Shiv, Xie, Wei, Patel, Dinshaw J., Meyer, Cindy, Garzia, Aitor, Tuschl, Thomas, Bozza, Patrícia T., Russo, James J., Souza, Thiago Moreno L., Ju, Jingyue
Natura: Artigo
Lingua:Inglês
Pubblicazione: Cold Spring Harbor Laboratory 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8312893/
https://ncbi.nlm.nih.gov/pubmed/34312622
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.07.21.453274
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi